{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:48:16Z","timestamp":1793965696138,"version":"4.8.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070513"],"award-info":[{"award-number":["82070513"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204544"],"award-info":[{"award-number":["82204544"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82100524"],"award-info":[{"award-number":["82100524"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.rpth.2025.103211","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:17:21Z","timestamp":1759796241000},"page":"103211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rivaroxaban in Chinese children with giant coronary artery aneurysms after Kawasaki disease"],"prefix":"10.1016","volume":"9","author":[{"given":"Guangan","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuecun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuna","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo R.","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4841-8206","authenticated-orcid":false,"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103211_bib1","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamapediatrics.2022.3756","article-title":"Incidence of Kawasaki disease before and after the COVID-19 pandemic in Japan: results of the 26th Nationwide Survey, 2019 to 2020","volume":"176","author":"Ae","year":"2022","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.rpth.2025.103211_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jpeds.2020.05.034","article-title":"Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease: the Nationwide Survey in Japan, 2017-2018","volume":"225","author":"Ae","year":"2020","journal-title":"J Pediatr"},{"key":"10.1016\/j.rpth.2025.103211_bib3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2188\/jea.JE20190065","article-title":"Epidemiologic features of Kawasaki disease in Shanghai from 2013 through 2017","volume":"30","author":"Xie","year":"2020","journal-title":"J Epidemiol"},{"key":"10.1016\/j.rpth.2025.103211_bib4","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1542\/peds.2008-2187","article-title":"Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006","volume":"123","author":"Huang","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.rpth.2025.103211_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s10067-016-3512-6","article-title":"National survey of pediatric hospitalizations due to Kawasaki disease and coronary artery aneurysms in the USA","volume":"36","author":"Okubo","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rpth.2025.103211_bib6","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1253\/circj.CJ-19-1094","article-title":"Japanese Circulation Soc. Joint Working Group. JCS\/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease","volume":"84","author":"Fukazawa","year":"2020","journal-title":"Circ J"},{"key":"10.1016\/j.rpth.2025.103211_bib7","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1161\/CIR.0000000000001295","volume":"150","author":"Jone","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2025.103211_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/blood.V70.1.165.165","article-title":"Development of the human coagulation system in the full-term infant","volume":"70","author":"Andrew","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103211_bib9","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1160\/TH05-01-0047","article-title":"Developmental haemostasis. Impact for clinical haemostasis laboratories","volume":"95","author":"Monagle","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103211_bib10","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood.V94.9.3007","article-title":"Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients","volume":"94","author":"Streif","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103211_bib11","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/blood.V80.8.1998.1998","article-title":"Maturation of the hemostatic system during childhood","volume":"80","author":"Andrew","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103211_bib12","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1253\/circj.CJ-08-0931","article-title":"Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease","volume":"73","author":"Suda","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.rpth.2025.103211_bib13","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939\u2014an oral, direct factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103211_bib14","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","article-title":"Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial","volume":"7","author":"Male","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2025.103211_bib15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.021765","article-title":"Thromboprophylaxis for children post-Fontan procedure: insights from the UNIVERSE Study","volume":"10","author":"McCrindle","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.rpth.2025.103211_bib16","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/S2352-3026(20)30368-9","article-title":"Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b\/3, non-inferiority trial","volume":"8","author":"Halton","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2025.103211_bib17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2019000998","article-title":"Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children","volume":"135","author":"Brand\u00e3o","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103211_bib18","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/psp4.12830","article-title":"Model-informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease","volume":"11","author":"Willmann","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.rpth.2025.103211_bib19","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.jacc.2023.10.010","article-title":"Apixaban for prevention of thromboembolism in pediatric heart disease","volume":"82","author":"Payne","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2025.103211_bib20","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2022.09.031","article-title":"Edoxaban for thromboembolism prevention in pediatric patients with cardiac disease","volume":"80","author":"Portman","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2025.103211_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2133\/dmpk.DMPK-12-RG-034","article-title":"Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation","volume":"28","author":"Tanigawa","year":"2013","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.rpth.2025.103211_bib22","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1038\/s41401-022-00892-9","article-title":"Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation","volume":"43","author":"Liu","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.rpth.2025.103211_bib23","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.3390\/pharmaceutics14081744","article-title":"Population pharmacokinetics and dose optimization based on renal function of rivaroxaban in Thai patients with non-valvular atrial fibrillation","volume":"14","author":"Singkham","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.rpth.2025.103211_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.43801","article-title":"DOACs in patients with giant coronary artery aneurysms after Kawasaki disease","volume":"6","author":"Dummer","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.rpth.2025.103211_bib26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/MPH.0000000000002690","article-title":"Pediatric thromboprophylaxis of large coronary artery aneurysm using rivaroxaban","volume":"45","author":"Montanez","year":"2023","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.rpth.2025.103211_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100140","article-title":"What did we learn (and did not learn) from the pediatric direct oral anticoagulant trials, and how might we better design pediatric anticoagulant trials in the future?","volume":"7","author":"Betensky","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103211_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.echo.2010.10.004","article-title":"New equations and a critical appraisal of coronary artery Z scores in healthy children","volume":"24","author":"Dallaire","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.rpth.2025.103211_bib29","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association","volume":"135","author":"McCrindle","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2025.103211_bib31","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jtha.2023.03.004","article-title":"Updated guidance for efficacy and safety outcomes for clinical trials in venous thromboembolism in children: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis","volume":"21","author":"Whitworth","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103211_bib32","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1055\/a-1450-8178","article-title":"2021 Update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants","volume":"121","author":"Douxfils","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103211_bib33","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.3390\/ph17111431","article-title":"Efficacy and safety of rivaroxaban, apixaban, and edoxaban for nonvalvular atrial fibrillation based on blood coagulation activity and drug plasma concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry","volume":"17","author":"Suwa","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.rpth.2025.103211_bib34","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1160\/TH07-12-0714","article-title":"Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"100","author":"Mueck","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103211_bib35","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jpba.2014.08.011","article-title":"Simultaneous determination of rivaroxaban and dabigatran levels in human plasma by high-performance liquid chromatography-tandem mass spectrometry","volume":"100","author":"Korostelev","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.rpth.2025.103211_bib36","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1111\/jth.12702","article-title":"Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS\/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants","volume":"12","author":"Schmitz","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103211_bib37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1160\/TH11-06-0391","article-title":"Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls","volume":"107","author":"Samama","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103211_bib38","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/pharmaceutics15020588","article-title":"Is a lower dose of rivaroxaban required for Asians? A systematic review of a population pharmacokinetics and pharmacodynamics analysis of rivaroxaban","volume":"15","author":"Liu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.rpth.2025.103211_bib39","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/psp4.12688","article-title":"Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions","volume":"10","author":"Willmann","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.rpth.2025.103211_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","article-title":"Human renal function maturation: a quantitative description using weight and postmenstrual age","volume":"24","author":"Rhodin","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.rpth.2025.103211_bib41","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/cts.12766","article-title":"Rivaroxaban precision dosing strategy for real-world atrial fibrillation patients","volume":"13","author":"Konicki","year":"2020","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.rpth.2025.103211_bib42","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1503\/cmaj.070186","article-title":"Drug\u2013drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding","volume":"177","author":"Delaney","year":"2007","journal-title":"CMAJ"},{"key":"10.1016\/j.rpth.2025.103211_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/archinte.167.2.117","article-title":"Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials","volume":"167","author":"Dentali","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rpth.2025.103211_bib44","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103211_bib45","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103211_bib46","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/jth.14813","article-title":"Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation","volume":"18","author":"Young","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103211_bib47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jth.15563","article-title":"Inter- and intra-individual concentrations of direct oral anticoagulants: the KIDOAC study","volume":"20","author":"Toorop","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103211_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.rpth.2025.103211_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-021-00595-9","article-title":"Estimation of ontogeny functions for renal transporters using a combined population pharmacokinetic and physiology-based pharmacokinetic approach: application to OAT1,3","volume":"23","author":"Cristea","year":"2021","journal-title":"AAPS J"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925005357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925005357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T02:46:46Z","timestamp":1767062806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925005357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2475037925005357"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103211","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rivaroxaban in Chinese children with giant coronary artery aneurysms after Kawasaki disease","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103211","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103211"}}